RT Journal Article
SR Electronic
T1 Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 367
OP 374
VO 66
IS 6
A2 Donald G. Vidt
A1 Larry W. Moreland
YR 1999
UL http://www.ccjm.org/content/66/6/367.abstract
AB Infliximab and etanercept, both approved by the FDA in 1998, are examples of a new class of disease-modifying antirheumatic drugs that interfere with the action of tumor necrosis factor alpha, one of the key cytokines that promote inflammation. Infliximab is approved for Crohn disease and etanercept for rheumatoid arthritis. Both show promise in treating rheumatoid arthritis, although the long-term risks and benefits of these drugs are not yet known.